A comprehensive summary of the FDA Form 483 issued to Aurobindo Pharma Limited,
Unit VII (Inspection dated Jan 28 – Feb 10 2026), including what went wrong at the quality system level — root causes, system failures, and broader quality-management insights
Why “Precision” Isn’t Enough for the FDA: A Lesson in Method Equivalency.
I’ve been diving deep into a specific FDA 483 observation recently that every Analytical Lead and QA Manager should keep on their radar. It highlights a common trap: confusing
Regulatory Enforcement Alert — FDA Cracks Down on Misleading Claims in GLP-1 & Compounded Drug Marketing.
The pharmaceutical and compounding landscape is witnessing a significant regulatory shift.The U.S. Food and Drug Administration (FDA) is actively enforcing federal drug marketing a
Another FDA 483 highlighting critical data integrity failures at a sterile manufacturing site in India.
A recent U.S. Food and Drug Administration 483 inspection at Maiva Pharma Pvt. Ltd. (Hosur, Tamil Nadu, India) identified serious deficiencies in the control of original CGMP manuf